Journal: Vaccine

Article Title: Humoral immune response characterization of heterologous prime-boost vaccination with CoronaVac and BNT162b2

doi: 10.1016/j.vaccine.2022.07.023

Figure Lengend Snippet: Fc-mediated functions and RBD-ACE2 binding inhibition of specific serum anti-RBD immunoglobulins . Figure shows ADCC (A) and ADCP (B) Fc-mediated functions of serum anti-RBD immunoglobulin in 20 individuals early after two doses of Coronavac (t 1 ) and after heterologous booster with BNT162b2 (t 3 ). Endpoint titers were calculated by interpolating the reciprocal of serum dilutions to baseline, whose values were determined for each plate as the mean signal in absence of serum plus three standard deviations. Inhibition of RBD-ACE2 binding (C) and serum anti-RBD IgG levels (D) were measured in the same samples, showing a similar behavior over time. Comparison of the RBD-ACE2 binding inhibition activity against SARS-CoV-2 Wuhan and Omicron variants were carried out by sVNT in these 20 samples (E). Numbers represents median values and the interquartile range (in parentheses). Comparisons between groups were carried out using Wilcoxon test. *p < 0.05, ** p = 0.01–0.001, *** p < 0.001. BAU, binding antibody units; AU, arbitrary units.

Article Snippet: The blockade of RBD-ACE2 interaction by specific anti-SARS-CoV-2 antibodies was analyzed by using an in vitro surrogate virus neutralization test (sVNT; cPassTM SARS-CoV-2 Neutralization Antibody Detection Kit, GenScript®) in serum from individuals who received heterologous vaccination at t 1 and t 2 (post-2D with CoronaVac) and at t 3 and t 4 (post-3D with BNT162b2), according to manufacturer’s instructions.

Techniques: Binding Assay, Inhibition, Comparison, Activity Assay

Journal: Chemical Science

Article Title: Diagnostics and analysis of SARS-CoV-2: current status, recent advances, challenges and perspectives

doi: 10.1039/d2sc06665c

Figure Lengend Snippet: Illustration of the LF-sVNT protocol and example sensorgrams. (A) First cycle measuring the binding ability of RBD to ACE2 after neutralization. (B) Second cycle measuring the full binding ability of RBD without neutralization. Reproduced with permission from J. Clin. Microbiol. , 2021, 59 , e0019321, 10.1128/JCM.00193-21.

Article Snippet: Michiels et al. compared the sVNT commercial kit (GenScript cPassTM) with a live virus neutralization assay and Luminex multiplex immunoassay (MIA), and studied two different cohorts using these three methods.

Techniques: Binding Assay, Neutralization

Journal: PLoS ONE

Article Title: Early detection of neutralizing antibodies against SARS-CoV-2 in COVID-19 patients in Thailand

doi: 10.1371/journal.pone.0246864

Figure Lengend Snippet: The serology test results of 0–7, 8–14, 15–21, 22–28 days after symptom onset were compared (lateral axis), respectively. Each dot represents one tested specimen and the vertical axis represents the %inhibition of SARS-CoV-2 NAbs tested by sVNT. The dash line represents the cutoff at 20% inhibition. The horizontal lines indicates the median interquartile range (IQR). The p values were calculated from two-tailed test.

Article Snippet: Blood specimens from patients with PCR-confirmed COVID-19 were tested for NAbs against SARS-CoV-2 antibodies using sVNT assay (cPassTM, GenScript USA), according to the manufacturer’s instructions.

Techniques: Inhibition, Two Tailed Test

Journal: PLoS ONE

Article Title: Early detection of neutralizing antibodies against SARS-CoV-2 in COVID-19 patients in Thailand

doi: 10.1371/journal.pone.0246864

Figure Lengend Snippet: Every dot represents one tested specimen and the vertical axis represents the %inhibition of SARS-CoV-2 NAbs tested by sVNT. The dashed line represents the cutoff at 20% inhibition. The horizontal lines indicate the median interquartile range (IQR). The p values were calculated from two-tailed test.

Article Snippet: Blood specimens from patients with PCR-confirmed COVID-19 were tested for NAbs against SARS-CoV-2 antibodies using sVNT assay (cPassTM, GenScript USA), according to the manufacturer’s instructions.

Techniques: Inhibition, Two Tailed Test

Journal: PLoS ONE

Article Title: Early detection of neutralizing antibodies against SARS-CoV-2 in COVID-19 patients in Thailand

doi: 10.1371/journal.pone.0246864

Figure Lengend Snippet: Every dot represents one tested specimen and the vertical axis represents the %inhibition of SARS-CoV-2 NAbs tested by sVNT. The dashed line represents the cutoff at 20% inhibition. The horizontal lines indicate the median interquartile range (IQR). The p values were calculated from two-tailed test.

Article Snippet: Blood specimens from patients with PCR-confirmed COVID-19 were tested for NAbs against SARS-CoV-2 antibodies using sVNT assay (cPassTM, GenScript USA), according to the manufacturer’s instructions.

Techniques: Inhibition, Two Tailed Test

Journal: Journal of Virological Methods

Article Title: Evaluation of a surrogate virus neutralization test for high-throughput serosurveillance of SARS-CoV-2

doi: 10.1016/j.jviromet.2021.114228

Figure Lengend Snippet: Sensitivity of the different serological tests and cut-offs used based on the final serum panels. Values between brackets represent 95 % confidence intervals on the estimations.

Article Snippet: Here, we performed an independent evaluation of a commercially available surrogate virus neutralization test (sVNT, GenScript cPassTM) that can be done without biosafety level 3 containment in less than 2 h. When using the cVNT and a Luminex multiplex immunoassay (MIA) as reference, the sVNT obtained a sensitivity of 94 % (CI 90–96 %) on a panel of 317 immune sera that were obtained from hospitalized and mild COVID-19 cases from Belgium and a sensitivity of 88 % (CI 81–93 %) on a panel of 184 healthcare workers from the Democratic Republic of Congo.

Techniques: Luminex

Journal: Journal of Virological Methods

Article Title: Evaluation of a surrogate virus neutralization test for high-throughput serosurveillance of SARS-CoV-2

doi: 10.1016/j.jviromet.2021.114228

Figure Lengend Snippet: Correlations between the percentage of inhibition measured by the surrogate viral neutralisation test (sVNT) and the log(dilution factors or signal-to-noise ratio) for the conventional viral neutralization test (cVNT) or the Luminex multiplex immunological assay (MIA) as calculated by the nonparametric Spearman correlation test (r s ). Seropositivity cut-off levels for the sVNT are indicated by the dashed grey lines at 20 or 30 % inhibition. Negative samples on the cVNT or MIA were not included in these figures.

Article Snippet: Here, we performed an independent evaluation of a commercially available surrogate virus neutralization test (sVNT, GenScript cPassTM) that can be done without biosafety level 3 containment in less than 2 h. When using the cVNT and a Luminex multiplex immunoassay (MIA) as reference, the sVNT obtained a sensitivity of 94 % (CI 90–96 %) on a panel of 317 immune sera that were obtained from hospitalized and mild COVID-19 cases from Belgium and a sensitivity of 88 % (CI 81–93 %) on a panel of 184 healthcare workers from the Democratic Republic of Congo.

Techniques: Inhibition, Neutralization, Luminex, Multiplex Assay

Journal: bioRxiv

Article Title: SARS-CoV-2 exposure in wild white-tailed deer ( Odocoileus virginianus )

doi: 10.1101/2021.07.29.454326

Figure Lengend Snippet: Serum samples were tested using the Genscript cPass™ surrogate virus neutralization test (sVNT).

Article Snippet: Samples were tested using the species and isotype independent Genscript cPassTM surrogate virus neutralization test (sVNT) in an ELISA format.

Techniques: Virus, Neutralization